Healthy Volunteers
Conditions
Brief summary
The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.
Detailed description
This sequential study will be divided in two parts, Part A and Part B. Part A will consist of 3 cohorts (Cohorts A1, A2, and A3) in which participants will be randomized to receive a single dose of Lu AG046466 or a matching placebo orally. After completing the safety review of data from Cohort A1, the study will proceed in Cohorts A2 and A3, with an increased dose of Lu AG046466 or matching placebo being administered to Japanese and Caucasian participants. Part B dosing will only be initiated after completion of Part A. Part B will consist of 1 cohort (Cohort B1), to which multiple dose of Lu AG046466 or matching placebo will be administered after dose titration.
Interventions
DRUGLu AG06466
Lu AG06466 will be administered per schedule specified in the arm.
DRUGPlacebo
Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
Sponsors
H. Lundbeck A/S
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* The participant has a BMI ≥18.5 and ≤25 kilograms (kg)/square meter (m\^2) or ≤30 kg/m\^2 for Japanese and Caucasian participants, respectively, and a body weight ≥50 kilograms (kg) at the screening visit and at the baseline visit. * The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, a neurological examination, vital signs, electrocardiograms (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.
Exclusion criteria
* The participant has taken disallowed medication \<1 week prior to the first dose of study drug or \<5 half-lives of the disallowed medication as concomitant use prior to the screening visit. * The participant has or has had any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, hematological, dermatological, venereal, neurological, or psychiatric disease or other major disorder. * The participant has had a clinically significant illness \<4 weeks prior to the first dose of study drug. * The participant has received a SARS-CoV-2 (COVID-19) vaccination \<30 days prior to the first dose of study drug. Note: Other inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A: Number of Participants With Adverse Events | Baseline up to Day 12 |
| Part B: Number of Participants With Adverse Events | Baseline up to Day 26 |
| Part A: Area Under the Plasma Concentration-Time Curve of Lu AG06466 and Metabolite Lu AG06988 From Zero to Infinity (AUC0-inf) | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 3 |
| Part B: Area Under the Plasma Concentration-Time Curve of Lu AG06466 and Metabolite Lu AG06988 in a Dosing Interval (AUC0-τ) | 0 (pre-dose) up to 24 hours post-dose on Day 15 |
| Part A: Maximum Observed Plasma Concentration (Cmax) of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 3 |
| Part B: Cmax of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 24 hours post-dose on Day 1 and Day 15 |
| Part A: Nominal Time Corresponding to the Occurrence of Cmax (Tmax) of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 3 |
| Part B: Tmax of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 24 hours post-dose on Day 1 and Day 15 |
| Part A: Apparent Elimination Half-Life (t1/2) of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 3 |
| Part B: t1/2 of Lu AG06466 and Metabolite Lu AG06988 | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 17 |
| Part A: Metabolic Ratio of AUC0-inf (MRAUC0-inf): AUC0-inf, Lu AG06988/AUC0-inf, Lu AG06466 | 0 (pre-dose) up to 48 hours post-dose on Day 1 to Day 3 |
Countries
Japan
Outcome results
None listed